Tianjin Development (00882.HK) announced its unaudited financial results of the subsidiary Tianjin Lisheng Pharmaceutical Co., Ltd. ("Lisheng Pharmaceutical") for the six months ended June 30, 2022. The company achieved total operating income of approximately RMB 615 million (the same below) during the period, an increase of 4.67% year-on-year, and net profit attributable to shareholders of approximately RMB 71.9539 million, an increase of 17.47% year-on-year, and basic income per share of RMB 0.39.
As of the close of August 24, 2022, Tianjin Development (00882.HK) closed at 1.58 yuan, down 1.25%, with a turnover rate of 0.02%, a trading volume of 174,000 shares and a trading volume of 275,500 yuan. Investment banks have little attention to the stock, and no investment bank has given it a rating within 90 days.
Tianjin Development has a market value of 1.695 billion yuan, ranking 19th in the power industry. The main indicators are shown in the table below:
and above are compiled by Securities Star based on public information and have nothing to do with the position of this site. Securities Star strives but does not guarantee the accuracy, completeness, validity, timeliness of all or part of the content of this information (including but not limited to text, video, audio, data and charts). If there are any problems, please contact us. This article is a data compilation and does not constitute any investment advice to you. Investment is risky, so please make prudent decisions.
